ANUHPHR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Anuh Pharma Says Maharashtra Facility Undergone Audit By EDQM
March 6 (Reuters) - Anuh Pharma Ltd ANUH.NS:
ANUH PHARMA LTD - MAHARASHTRA FACILITY UNDERGONE AUDIT BY EDQM
ANUH PHARMA LTD - FACILITIES WERE FOUND TO BE COMPLIANT DURING EDQM AUDIT
Further company coverage: ANUH.NS
March 6 (Reuters) - Anuh Pharma Ltd ANUH.NS:
ANUH PHARMA LTD - MAHARASHTRA FACILITY UNDERGONE AUDIT BY EDQM
ANUH PHARMA LTD - FACILITIES WERE FOUND TO BE COMPLIANT DURING EDQM AUDIT
Further company coverage: ANUH.NS
Anuh Pharma June-Quarter PAT 95.1 Million Rupees
Aug 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA JUNE-QUARTER PAT 95.1 MILLION RUPEES
ANUH PHARMA JUNE-QUARTER REVENUE FROM OPERATIONS 1.38 BILLION RUPEES
Source text for Eikon: ID:nBSE82kZjz
Further company coverage: ANUH.BO
Aug 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA JUNE-QUARTER PAT 95.1 MILLION RUPEES
ANUH PHARMA JUNE-QUARTER REVENUE FROM OPERATIONS 1.38 BILLION RUPEES
Source text for Eikon: ID:nBSE82kZjz
Further company coverage: ANUH.BO
Anuh Pharma Says Invests In Houban Energy 5 For Solar Project
April 4 (Reuters) - Anuh Pharma Ltd ANUH.BO:
INVESTMENT IN HOUBAN ENERGY 5 FOR SOLAR PROJECT
Source text for Eikon: ID:nBSE7MmGfl
Further company coverage: ANUH.BO
April 4 (Reuters) - Anuh Pharma Ltd ANUH.BO:
INVESTMENT IN HOUBAN ENERGY 5 FOR SOLAR PROJECT
Source text for Eikon: ID:nBSE7MmGfl
Further company coverage: ANUH.BO
Anuh Pharma Gets EDQM Approval For CEP Of Sulfadoxine API
Feb 28 (Reuters) - Anuh Pharma Ltd ANUH.BO:
APPROVAL FROM EDQM FOR CEP OF SULFADOXINE API WHICH IS AN ANTI-MALARIAL DRUG
Source text for Eikon: ID:nBSE75hVMs
Further company coverage: ANUH.BO
Feb 28 (Reuters) - Anuh Pharma Ltd ANUH.BO:
APPROVAL FROM EDQM FOR CEP OF SULFADOXINE API WHICH IS AN ANTI-MALARIAL DRUG
Source text for Eikon: ID:nBSE75hVMs
Further company coverage: ANUH.BO
Anuh Pharma Ltd Dec-Quarter Pat Rises
Feb 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD DEC-QUARTER PAT 191.1 MILLION RUPEES VERSUS 93.1 MILLION RUPEES
ANUH PHARMA LTD DEC-QUARTER REVENUE FROM OPERATIONS 1.72 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE83lMqK
Further company coverage: ANUH.BO
Feb 9 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ANUH PHARMA LTD DEC-QUARTER PAT 191.1 MILLION RUPEES VERSUS 93.1 MILLION RUPEES
ANUH PHARMA LTD DEC-QUARTER REVENUE FROM OPERATIONS 1.72 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE83lMqK
Further company coverage: ANUH.BO
Anuh Pharma Got Approval From EDQM For CEP Of Gliclazide API
Aug 11 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ECEIVED APPROVAL FROM EDQM FOR CEP OF GLICLAZIDE API
Source text for Eikon: ID:nBSE1RMk0L
Further company coverage: ANUH.BO
Aug 11 (Reuters) - Anuh Pharma Ltd ANUH.BO:
ECEIVED APPROVAL FROM EDQM FOR CEP OF GLICLAZIDE API
Source text for Eikon: ID:nBSE1RMk0L
Further company coverage: ANUH.BO
Anuh Pharma Received Approval From EDQM For CEP Of Azithromycin API
July 13 (Reuters) - Anuh Pharma Ltd ANUH.BO:
RECEIVED APPROVAL FROM EDQM FOR CEP OF AZITHROMYCIN API, A BROAD SPECTRUM MACROLIDE ANTIBIOTIC
Further company coverage: ANUH.BO
July 13 (Reuters) - Anuh Pharma Ltd ANUH.BO:
RECEIVED APPROVAL FROM EDQM FOR CEP OF AZITHROMYCIN API, A BROAD SPECTRUM MACROLIDE ANTIBIOTIC
Further company coverage: ANUH.BO
Events:
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Anuh Pharma do?
Anuh Pharma Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and also deals in bulk drugs, chemicals, and pharmaceutical formulations.
Who are the competitors of Anuh Pharma?
Anuh Pharma major competitors are Bharat Parenterals, Wanbury, Fredun Pharma, Kilitch Drugs(India), Prevest Denpro, Jenburkt Pharma, Syncom Formulations. Market Cap of Anuh Pharma is ₹736 Crs. While the median market cap of its peers are ₹722 Crs.
Is Anuh Pharma financially stable compared to its competitors?
Anuh Pharma seems to be less financially stable compared to its competitors. Altman Z score of Anuh Pharma is 5.38 and is ranked 4 out of its 8 competitors.
Does Anuh Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Anuh Pharma latest dividend payout ratio is 15.87% and 3yr average dividend payout ratio is 21.48%
How has Anuh Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is Anuh Pharma balance sheet?
Balance sheet of Anuh Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Anuh Pharma improving?
No, profit is decreasing. The profit of Anuh Pharma is ₹41.82 Crs for TTM, ₹47.35 Crs for Mar 2025 and ₹60.06 Crs for Mar 2024.
Is the debt of Anuh Pharma increasing or decreasing?
Yes, The net debt of Anuh Pharma is increasing. Latest net debt of Anuh Pharma is -₹2.15 Crs as of Sep-25. This is greater than Mar-25 when it was -₹28.96 Crs.
Is Anuh Pharma stock expensive?
Anuh Pharma is not expensive. Latest PE of Anuh Pharma is 17.6, while 3 year average PE is 18.51. Also latest EV/EBITDA of Anuh Pharma is 12.73 while 3yr average is 13.04.
Has the share price of Anuh Pharma grown faster than its competition?
Anuh Pharma has given lower returns compared to its competitors. Anuh Pharma has grown at ~13.58% over the last 4yrs while peers have grown at a median rate of 16.95%
Is the promoter bullish about Anuh Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Anuh Pharma is 71.82% and last quarter promoter holding is 71.82%.
Are mutual funds buying/selling Anuh Pharma?
There is Insufficient data to gauge this.